Zymogenetics initiated by Global Crown at neutral

Zymogenetics Inc. coverage was initiated by Global Crown Capital analyst Kate Winkler at a neutral rating. Zymogenetics has excellent long-term prospects with valuable intellectual property and partnerships, Global Crown said, but visibility among investors is fairly high, and with a low float in the stock it appears fairly valued at present. Seattle-based Zymogenetics products include Novolin and NovoRapid for the treatment of diabetes. Zymogenetics shares Tuesday rose $0.07, or 0.37%, to $19.07 on volume of 121,355 shares versus the three-month running average of 122,964 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.